STOCK TITAN

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released a new CEO Corner segment featuring CEO Brad Hauser. The segment, now available on the company's website, discusses details about the company's recently announced planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial.

Autonomix Medical (NASDAQ: AMIX), un'azienda di dispositivi medici specializzata in trattamenti di precisione mirati ai nervi, ha pubblicato un nuovo segmento chiamato CEO Corner con il CEO Brad Hauser. Il segmento, ora disponibile sul sito web dell'azienda, illustra i dettagli del recente studio di espansione di mercato pianificato (PoC 2) della sua prova di concetto.

Autonomix Medical (NASDAQ: AMIX), una empresa de dispositivos médicos centrada en tratamientos precisos dirigidos a los nervios, ha lanzado un nuevo segmento llamado CEO Corner con el CEO Brad Hauser. El segmento, ya disponible en el sitio web de la compañía, aborda detalles sobre el estudio de expansión de mercado planificado recientemente anunciado (PoC 2) de su ensayo de prueba de concepto.

Autonomix Medical (NASDAQ: AMIX)는 정밀 신경 타깃 치료에 중점을 둔 의료기기 회사로, CEO 브래드 하우저가 출연하는 새로운 CEO 코너 영상을 공개했습니다. 이 영상은 현재 회사 웹사이트에서 확인할 수 있으며, 최근 발표된 개념 증명 시험의 후속 시장 확장 연구 단계(PoC 2)에 대한 세부 내용을 다룹니다.

Autonomix Medical (NASDAQ: AMIX), une entreprise de dispositifs médicaux spécialisée dans les traitements de précision ciblant les nerfs, a publié un nouveau segment CEO Corner avec le PDG Brad Hauser. Ce segment, désormais disponible sur le site web de l'entreprise, présente les détails de l'étude d'expansion de marché prévue récemment annoncée (PoC 2) de son essai de preuve de concept.

Autonomix Medical (NASDAQ: AMIX), ein Medizintechnikunternehmen, das sich auf präzise nervenorientierte Behandlungen spezialisiert hat, hat ein neues CEO Corner Segment mit CEO Brad Hauser veröffentlicht. Das Segment, das jetzt auf der Website des Unternehmens verfügbar ist, erläutert Details zur kürzlich angekündigten geplanten Folge-Markterweiterungsstudie (PoC 2) seiner Machbarkeitsstudie.

Positive
  • None.
Negative
  • None.

THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company’s recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial.

The CEO Corner segment is now available here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com


FAQ

What did Autonomix Medical (AMIX) announce in their latest CEO Corner segment?

CEO Brad Hauser discussed the company's planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial in the latest CEO Corner segment.

Who is the CEO of Autonomix Medical (AMIX)?

Brad Hauser is the CEO of Autonomix Medical.

Where can investors find Autonomix Medical's (AMIX) latest CEO Corner segment?

The CEO Corner segment is available on Autonomix Medical's company website.

What is Autonomix Medical's (AMIX) main business focus?

Autonomix Medical is a medical device company dedicated to advancing precision nerve-targeted treatments.
Autonomix Medical Inc

NASDAQ:AMIX

AMIX Rankings

AMIX Latest News

AMIX Latest SEC Filings

AMIX Stock Data

3.95M
2.30M
19.52%
19.89%
3.08%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
THE WOODLANDS